trial

A Clinical Study to Evaluate the Bioavailability Between Two Products Containing Paliperidone 100 mg in the Form of a Prolonged Release Suspension for Injection in Patients With Schizophrenia Who Are Already Stabilized in This Treatment

NCTId NCT03425552
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1, Phase 2 · Completed
Enrollment 70 (actual)
Sponsored by Pharmathen S.A.
Primary completion 2019-05-02
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1, Phase 2
Status
Completed
Enrollment
70 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
None
Start
2018-03-11
Primary completion
2019-05-02
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Paliperidone

Sponsors

Pharmathen S.A.Lead Sponsor

Investigators

1
Lina SabbahStudy Director

Sites

3 total
Amman, JordanAr Ramtha, JordanIrbid, Jordan

Linked catalysts

1
A Clinical Study to Evaluate the Bioavailability Between Two Products Containing — primary completion2019-05-02

Facts & assertions

4 sourced
Enrollment
70
Phase
PHASE1,PHASE2
Primary Completion Date
2019-05-02
Status
COMPLETED
relationships
The graph out of here
drug
Paliperidone
drug
lead_sponsor
Pharmathen S.A.
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Lina Sabbah
person